文献速递外周动脉疾病

原发药物涂层球囊与药物洗脱支架治疗股腘动脉病变的荟萃分析

Primary Drug-Coated Balloon Versus Drug-Eluting Stent for Native Atherosclerotic Femoropopliteal Lesions: An Updated Systematic Review and Meta-Analysis.
PubMed 文献 · J Endovasc Ther · 2025-06-12

该系统评价与荟萃分析纳入11项研究(3项随机临床试验和8项队列研究)、共3137例患者3231处股腘动脉病变,比较原发药物涂层球囊(DCB)与药物洗脱支架(DES)的临床结局,结果显示两组在1年和2年的主要通畅率、临床驱动的靶病变血运重建、免于主要不良肢体事件及全因死亡率方面均无显著差异,DCB组辅助操作(如斑块旋切和补救性支架)需求显著更高。

要点

  • DCB与DES治疗股腘动脉病变在1年和2年的临床结局均无显著差异。
  • DCB组需要辅助操作(斑块旋切和补救性支架)的比率显著更高,OR 0.13(95%CI 0.09-0.18;p<0.001)。
  • 两种方法对复杂股腘动脉病变均有效且安全。

核心结论

  • DCB和DES两种方法治疗复杂股腘动脉病变均有效且安全,两组临床结局相当。
  • DCB组需要辅助操作如斑块旋切和补救性支架来优化结果。

研究设计与样本

  • 通过PubMed和Embase数据库进行全面文献检索,纳入直接比较原发DCB血管成形术与DES支架植入术结局的英文研究。
  • 共纳入11项研究(3项随机临床试验和8项队列研究),涉及3137例患者的3231处股腘动脉病变,DCB组1951处病变,DES组1280处病变。

主要发现

  • 两组在人口学特征、临床肢体表现、病变长度[DES 173.9±80.2 mm vs DCB 195.1±103.3 mm;OR -2.44;95%CI -11.26至6.38;p=0.59]和完全闭塞(OR 1.41;95%CI 0.87-2.27;p=0.16)方面无差异。
  • DCB组辅助操作(斑块旋切和补救性支架)的比率显著更高,OR 0.13(95%CI 0.09-0.18;p<0.001)。
  • 1年时DCB与DES的主要通畅率、临床驱动的靶病变血运重建、免于主要不良肢体事件和全因死亡率均无差异:OR 1.11(95%CI 0.74-1.66,p=0.61);OR 1.01(95%CI 0.72-1.41,p=0.97);OR 1.08(95%CI 0.69-1.69,p=0.74);OR 1.85(95%CI 0.82-4.17,p=0.14)。
  • 2年时DCB与DES的上述结局均无差异:OR 0.89(95%CI 0.64-1.23,p=0.47);OR 0.79(95%CI 0.49-1.27,p=0.32);OR 0.74(95%CI 0.49-1.10,p=0.14);OR 1.21(95%CI 0.75-1.96,p=0.44)。

临床怎么用

  • 对于症状性外周动脉疾病患者的原发股腘动脉病变,DCB和DES均可作为有效且安全的治疗选择,临床结局相当。
  • 使用DCB时,可能需要辅助操作如斑块旋切和补救性支架来优化结果。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the clinical outcomes after endovascular treatment of native femoropopliteal lesions with a drug-coated balloon (DCB) and drug-eluting stent (DES) as a primary option in patients with symptomatic peripheral artery disease. MATERIALS AND METHODS: A comprehensive literature search was performed through PubMed and Embase databases. Studies written in the English language and reporting a direct comparison of the outcomes between primary angioplasty with DCB and primary stenting with DES were included. The endpoints were considered the primary patency (PP), clinical-driven target lesion revascularization (cdTLR), major adverse limb events (free-MALE), and freedom from all-cause mortality. RESULTS: Eleven studies were considered eligible for the metanalysis (3 randomized clinical trials and 8 cohort studies). Overall, 3231 femoropopliteal lesions in 3137 patients were included, with DCB and DES performed in 1951 and 1280 lesions, respectively. No differences were found in demographics, clinical limb presentation, lesions length [173.9±80.2 mm DES vs 195.1±103.3 mm DCB; odds ratio (OR) -2.44; 95% confidence interval (CI) -11.26 to 6.38; p=0.59] and total occlusions (OR 1.41; 95% CI 0.87-2.27; p=0.16). In the DCB group, there was a significant rate of adjunctive procedures such as atherectomy and bailout stenting OR 0.13 (95% CI 0.09-0.18; p<0.001). No differences among PP, cdTLR, free-MALE and freedom from all-cause mortality at 1 year for DCB and DES: OR 1.11 (95% CI 0.74-1.66, p=0.61); OR 1.01 (95% CI 0.72-1.41, p=0.97); OR 1.08 (95% CI 0.69-1.69, p=0.74) and OR 1.85 (95% CI 0.82-4.17, p=0.14) respectively. No differences were found at 2 years: OR 0.89 (95% CI 0.64-1.23, p=0.47); OR 0.79 (95% CI 0.49-1.27, p=0.32); OR 0.74 (95% CI 0.49-1.10, p=0.14); OR 1.21 (95% CI 0.75-1.96, p=0.44) respectively. CONCLUSIONS: Both approaches proved to be effective and safe for treating complex femoropopliteal lesions, with comparable clinical outcomes between the 2 groups. In the DCB arm, adjunctive procedures such as atherectomy and bailout stenting were required to optimize the results.Clinical ImpactThe introduction of drug-coated technologies, such as drug-coated balloons (DCBs) and drug-eluting stents (DESs), has significantly improved clinical outcomes for native femoropopliteal lesions. However, despite ongoing advancements in drug-coated device technology, the optimal treatment approach remains unclear due to limited comparative data in the literature. This meta-analysis aims to bridge this gap by reviewing current evidence, highlighting the latest developments, and providing valuable insights that may aid clinical decision-making in the management of native femoropopliteal lesions.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Cosacco AM, Zenunaj G, Acciarri P, et al. Primary Drug-Coated Balloon Versus Drug-Eluting Stent for Native Atherosclerotic Femoropopliteal Lesions: An Updated Systematic Review and Meta-Analysis. J Endovasc Ther. 2025. PMID: 40509701. doi:10.1177/15266028251344877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。